

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/041,856	SLAUGENHAUPT ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Carla Myers	1634	

**All Participants:**

**Status of Application:** \_\_\_\_\_

(1) Carla Myers. (3) \_\_\_\_\_.

(2) Margaret Brivanlou. (4) \_\_\_\_\_.

**Date of Interview:** 6 September 2007

**Time:** \_\_\_\_\_

**Type of Interview:**

Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant  Applicant's representative)

Exhibit Shown or Demonstrated:  Yes  No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

Prior art documents discussed:

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

See *Continuation Sheet*

**Part III.**

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner indicated that in the advisory action of August 31, 2007 the previous after final amendment was not entered partly in view of the fact that the amendment to add claim 102 raised the issue of new matter and raised new issues under 35 USC 103 that required further search and consideration. The examiner also indicated that claim 100 should be amended to indicate that the kit contains both the probe to detect a FD1 mutation and a probe to detect a FD2 mutation.